Brooklyn Investment Group’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.34M Buy
7,323
+1,621
+28% +$299K 0.04% 423
2025
Q4
$1.01M Buy
5,702
+1,446
+34% +$236K 0.05% 346
2025
Q3
$537K Buy
4,256
+2
+0% +$270 0.07% 262
2025
Q2
$534K Buy
4,254
+3,325
+358% +$414K 0.07% 267
2025
Q1
$127K Buy
929
+309
+50% +$44.2K 0.03% 461
2024
Q4
$94.8K Buy
620
+517
+502% +$87.2K 0.03% 380
2024
Q3
$20K Buy
+103
New +$21.5K 0.01% 649

Other funds holding BIIB

Brooklyn Investment Group's BIIB Position: Q1 2026 in Review

Brooklyn Investment Group increased its Biogen (BIIB) stake by 28% in Q1 2026, buying an estimated $299K and bringing the position to 7,323 shares worth $1.34M. The position accounts for 0.04% of the portfolio, ranked #423.

Brooklyn Investment Group first reported a position in BIIB in Q3 2024 and has held it in 7 quarters since. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Brooklyn Investment Group held 7,323 shares of Biogen worth $1.34M as of Q1 2026.
  • Brooklyn Investment Group bought 1,621 Biogen shares in Q1 2026, an estimated $299K.
  • Biogen made up 0.04% of Brooklyn Investment Group's portfolio in Q1 2026, its #423 holding.
  • Brooklyn Investment Group first reported a position in Biogen in Q3 2024 and has held it in 7 quarters since.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.